Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Circulating miR-184 is a Potential Biomarker of Cardiac and Renal Damage in Anderson-Fabry Disease

ABSTRACT: Circulating miR-184 is a Potential Biomarker of Cardiac and Renal Damage in Anderson-Fabry Disease

PROVIDER: PRJNA680346 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Circulating miR-184 is a Potential Biomarker of Cardiac and Renal Damage in Anderson-Fabry Disease

Project description:The clinical symptoms of Fabry disease are caused by progressive accumulation of unprocessed globotriaosylceramide metabolite within cells, inducing multiple organ damage. Enzyme replacement therapy (ERT) is the only strategy to restore enzymatic activity, but a reliable biomarker to assess treatment response does not exist. Here, we identify circulating miR-184 as a sensitive marker of response to ERT and of clinical outcome for cardiac and kidney involvement.

2021-11-06 | GSE162042 | GEO

Fabry nephropathy transcriptome

Project description:Fabry nephropathy (FN) is a rare disorder caused by mutations in the alpha-galactosidase A gene. In this study we aim at providing a framework allowing selection of biomarkers and drug-targets. Two independent Fabry Nephropathy cohorts (FA.NO and CH.RO) were subjected to RNAseq from archival kidney biopsies taken prior and up to 10 years of Enzyme Replacement Therapy. Four compartments were laser capture microdissected (glomeruli, proximal tubuli, distal tubuli and arteries). We found several pathways that were consistently altered and that these kidney compartments’ transcriptional landscapes can be leveraged in the search for drug-targets and biomarkers.

2023-07-17 | GSE178947 | GEO

Fabry nephropathy transcriptome

Project description:Fabry nephropathy transcriptome

| PRJNA741535 | ENA

Expression of transcriptome analysis of human fabry kidney organoid

Project description:Kidney organoids in vitro model enabled identification of a novel mechanism that may be used for the treatment of Fabry disease.

2021-01-16 | GSE164941 | GEO

Transcriptomic analysis of microglia 4 month old ML4 Fabry and control mice

Project description:the study aims to describe the modifications occurring the microglia isolated from mouse models of 2 lysosomal storage diseases: Mucolipidosis type 4 and fabry disease.

2019-01-01 | GSE112895 | GEO

Escherichia coli strain:184/2aE | isolate:184/2aE

Project description:Escherichia coli strain:184/2aE | isolate:184/2aE Genome sequencing

| PRJNA719994 | ENA

Glaesserella sp. 15-184 strain:15-184-2

Project description:Glaesserella sp. 15-184 strain:15-184-2 Genome sequencing

| PRJNA397816 | ENA

Podocyte injury in Fabry nephropathy

Project description:Current therapies for Fabry disease are based on reversing intra-cellular accumulation of globotriaosylceramide (Gb3) by enzyme replacement (ERT) or chaperone mediated stabilization, thereby alleviating lysosome dysfunction. However, the therapeutic effect in the regression of end-organ damage (ie. kidney damage) is limited. Ultrastructural analysis of serial human kidney biopsies showed that long-term use of ERT reduced Gb3 accumulation in podocytes but did not alter podocyte injury. A novel CRISPR-/CAS9-mediated -Galactosidase knockout podocyte cell line confirmed ERT-mediated reversal of Gb3 accumulation without resolution of lysosomal dysfunction. Transcriptomic-based connectivity mapping and SILAC-based quantitative proteomics identified alpha-synuclein (SNCA) accumulation as a key event mediating podocyte injury.

2023-04-10 | GSE186258 | GEO

Sinorhizobium meliloti strain:184

Project description:Sinorhizobium meliloti 184 Resequencing

| PRJNA501482 | ENA

Prochlorococcus phage MED4-184

Project description:Cyanophage MED4-184 genome sequencing project

| PRJNA53293 | ENA